Fresh analysis reveals that patients who come off blockbuster slimming jabs like Wegovy and Mounjaro tend to recover shed pounds far faster than those who stop conventional diet and exercise plans.
Research printed in a prominent health publication shows that while overweight people often shed substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"People using these drugs need to be cognizant of the danger of fast weight regain when the therapy concludes," cautioned expert Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment mass within about a year and a half.
Comparing Therapies
The analysis, which examined dozens of studies involving over 9,000 of patients, compared the outcomes of these new drugs with other pills.
Researchers emphasize that people who shed pounds through dieting generally have a more gradual creep back—around 100 grams monthly—once they finish.
Understanding the Rapid Regain
Nutrition scientists believe the way of the jabs accounts for the accelerated weight return.
These medications mimic a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone levels several times higher than the body's typical production may cause the body to produce less of its own natural GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication means appetite is unsuppressed, making excessive eating much more probable."
A Chronic Disease?
The NHS advise the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
Many experts say that, considering the likelihood of relapse, the treatment might need to be long-term.
This view is supported by drug manufacturers, who note that the results "underscore the chronic nature of obesity," similar to managing diseases like high blood pressure.
Patient Accounts
People who have come off the jabs report a sudden resurgence of hunger.
"It was like a trigger activating and you're instantly ravenous," said one woman.
This challenge is exacerbated if patients have not adopted lasting dietary or behavioural modifications during treatment.
Widespread Adoption
Survey data suggest that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is more common among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a magic fix and lasting health benefits likely depends on integrated lifestyle management.
